CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dyax Corp. (Nasdaq:DYAX) announced today that it has entered into a non-exclusive agreement with Trubion Pharmaceuticals Inc. (Trubion) in the fields of protein therapeutics and diagnostics discovery. Under the agreement, Dyax will utilize its proprietary phage display libraries for the discovery of compounds that bind with high affinity and specificity to Trubion’s targets in the oncology and inflammation area.
